T0	Participants 65 122	postmenopausal patients with metastatic breast carcinoma:
T1	Participants 212 275	Breast cancer patients with prior response to endocrine therapy
T2	Participants 446 589	post menopausal patients who had disease progression after receiving antiestrogen therapy either for metastatic disease or as adjuvant therapy.
T3	Participants 598 669	In 2 multiinstitutional prospective trials, 683 postmenopausal patients
T4	Participants 1703 1759	postmenopausal patients with metastatic breast carcinoma